PL3941443T3 - Kompozycja o przedłużonym uwalnianiu zawierająca szczawian tapentadolu oraz sposób jej wytwarzania - Google Patents

Kompozycja o przedłużonym uwalnianiu zawierająca szczawian tapentadolu oraz sposób jej wytwarzania

Info

Publication number
PL3941443T3
PL3941443T3 PL20721145.9T PL20721145T PL3941443T3 PL 3941443 T3 PL3941443 T3 PL 3941443T3 PL 20721145 T PL20721145 T PL 20721145T PL 3941443 T3 PL3941443 T3 PL 3941443T3
Authority
PL
Poland
Prior art keywords
tapentadol
oxalate
preparation
sustained release
release composition
Prior art date
Application number
PL20721145.9T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthymios Koutris
Vasiliki SAMARA
Ioanna Koutri
Anastasia Kalaskani
Christina KIZIRIDI
Andreas KAKOURIS
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of PL3941443T3 publication Critical patent/PL3941443T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20721145.9T 2019-03-22 2020-03-20 Kompozycja o przedłużonym uwalnianiu zawierająca szczawian tapentadolu oraz sposób jej wytwarzania PL3941443T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20190100138A GR1009751B (el) 2019-03-22 2019-03-22 Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει οξαλικη ταπενταδολη και μεθοδος παρασκευης αυτου
PCT/EP2020/025139 WO2020192969A1 (en) 2019-03-22 2020-03-20 Sustained release composition comprising tapentadol oxalate and method of preparation thereof

Publications (1)

Publication Number Publication Date
PL3941443T3 true PL3941443T3 (pl) 2024-05-06

Family

ID=70456722

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20721145.9T PL3941443T3 (pl) 2019-03-22 2020-03-20 Kompozycja o przedłużonym uwalnianiu zawierająca szczawian tapentadolu oraz sposób jej wytwarzania

Country Status (19)

Country Link
US (1) US20220202720A1 (pl)
EP (1) EP3941443B1 (pl)
AU (1) AU2020248971A1 (pl)
BR (1) BR112021018896A2 (pl)
CA (1) CA3134455A1 (pl)
CY (1) CY1126748T1 (pl)
DK (1) DK3941443T3 (pl)
ES (1) ES2973959T3 (pl)
FI (1) FI3941443T3 (pl)
GR (1) GR1009751B (pl)
HR (1) HRP20240347T1 (pl)
HU (1) HUE066190T2 (pl)
LT (1) LT3941443T (pl)
PL (1) PL3941443T3 (pl)
PT (1) PT3941443T (pl)
RS (1) RS65287B1 (pl)
SI (1) SI3941443T1 (pl)
SM (1) SMT202400109T1 (pl)
WO (1) WO2020192969A1 (pl)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
FR2936709B1 (fr) 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
FR2959935B1 (fr) 2010-05-14 2013-02-08 Ethypharm Sa Forme pharmaceutique orale alcoolo-resistante
ES2628303T3 (es) 2011-06-01 2017-08-02 Fmc Corporation Formas de dosis sólidas de liberación controlada
EA201400172A1 (ru) * 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
WO2015120201A1 (en) * 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015145461A1 (en) * 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US10182992B2 (en) * 2014-04-07 2019-01-22 Patheon Softgels Inc. Abuse-deterrent controlled release formulations
US20180303757A1 (en) * 2015-10-23 2018-10-25 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
US20190054024A1 (en) * 2017-08-16 2019-02-21 HUMANWELL PHARMACEUTICAL US, Inc. Solid Dosage Forms

Also Published As

Publication number Publication date
SMT202400109T1 (it) 2024-05-14
CA3134455A1 (en) 2020-10-01
LT3941443T (lt) 2024-03-25
EP3941443B1 (en) 2023-12-13
HRP20240347T1 (hr) 2024-05-24
ES2973959T3 (es) 2024-06-25
CY1126748T1 (el) 2026-02-25
FI3941443T3 (fi) 2024-03-15
PT3941443T (pt) 2024-03-15
BR112021018896A2 (pt) 2021-11-30
GR1009751B (el) 2020-05-29
SI3941443T1 (sl) 2024-05-31
AU2020248971A1 (en) 2021-11-18
WO2020192969A1 (en) 2020-10-01
HUE066190T2 (hu) 2024-07-28
RS65287B1 (sr) 2024-04-30
EP3941443A1 (en) 2022-01-26
US20220202720A1 (en) 2022-06-30
DK3941443T3 (da) 2024-03-18

Similar Documents

Publication Publication Date Title
SG11202101814RA (en) Compositions of cxcr4 inhibitors and methods of preparation and use
ZA201708429B (en) Oral solid formulation containing irinotecan and method of preparing the same
SG11202009315WA (en) Formulation and method of preparation
SI3981390T1 (sl) Farmacevtska sestava lakozamida in njegova farmacevtska priprava
EP3606493A4 (en) DENTAL CEMENT COMPOSITIONS AND METHOD OF USE
LT3675816T (lt) Pailginto atpalaidavimo anestetinės kompozicijos ir jų gamybos būdai
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
ZA202007392B (en) Concrete release agent and preparation method therefor
PL4048230T3 (pl) Doustne kompozycje gliptiny i sposób ich wytwarzania
IL273690A (en) Gingivitis vaccine and related preparations and methods of using it
EP3813842A4 (en) PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF
SMT202400109T1 (it) Composizione a rilascio prolungato comprendente ossalato di tapentadolo e metodo di preparazione relativo
ZA201902045B (en) Sustained release composition comprising tapentadol oxalate and method of preparation thereof
SI3946276T1 (sl) Sestavek s podaljšanim sproščanjem, ki obsega tapentadol, in postopek njegove priprave
GB202009592D0 (en) Formulations of tie-2 activators and methods of use thereof
ZA201902044B (en) Sustained release composition comprising tapentadol and method of preparation thereof
ZA202000609B (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
PL3692127T3 (pl) Substancje pro-zapachowe i sposób ich wytwarzania
SG11202002351SA (en) Poloxamer compositions and methods of making and using same
PL3692126T3 (pl) Substancje pro-zapachowe i sposób ich wytwarzania
GB201810395D0 (en) Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
ZA201905253B (en) Pharmaceutical composition comprising naltrexone microspheres and method of preparation thereof
ZA201806527B (en) Pharmaceutical composition comprising vildagliptin and metformin and method of preparation thereof
ZA202206932B (en) Pharmaceutical composition of casr modulators and methods and uses thereof
GB201902017D0 (en) Methods of preparing and using perfume compositions